Venous Thromboembolism study: Anticoagulation Therapy
Official title Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
ClinicalTrials.gov ID: NCT06603870
What this study is testing
What is Anticoagulation Therapy?
Anticoagulation Therapy is an investigational medicine, taken by mouth twice daily, being studied as a potential treatment for venous thromboembolism.
Also referred to as Apixaban.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to find out the best way to manage patients after the initial 3‑month anticoagulation period for catheter‑related upper‑arm DVT.
- Who it's for
- Adults with cancer who have had a catheter‑related upper‑extremity deep vein thrombosis and have completed at least three months of therapeutic anticoagulation.
- What's involved
- Participants will follow a specific management strategy and attend scheduled clinic visits and tests to monitor their condition.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients (≥ 18 years old) with active cancer, defined as cancer (other than localized non-melanoma skin cancer) diagnosed or treated within 6...
- Objectively confirmed catheter-related upper extremity DVT and treated with any standard therapeutic anticoagulation (including LMWH dose reduction...
- Able and willing to provide informed consent.
You likely can't join if
- Active bleeding or other reasons for which anticoagulation is contraindicated.
- Other indications requiring ongoing therapeutic dose of anticoagulation as deemed necessary by treating physicians (such as atrial fibrillation...
- Anticoagulation has been permanently stopped or reduced to prophylactic dose for \> 5 days prior to enrollment for any reasons.
- Pregnancy or breast feeding in patients who are prescribed a direct oral anticoagulant.
- Concomitant use of strong inhibitors or inducers of both cytochrome P450 3A4 and P-glycoprotein in patients who are prescribed a direct oral...
- Cancer is in remission and CVC is removed prior to enrollment.
See the full eligibility criteria
- Adult patients (≥ 18 years old) with active cancer, defined as cancer (other than localized non-melanoma skin cancer) diagnosed or treated within 6 months, or the presence of metastatic, recurrent, or progressive...
- Objectively confirmed catheter-related upper extremity DVT and treated with any standard therapeutic anticoagulation (including LMWH dose reduction to 75% after the first month) for at least 3 months.
- Able and willing to provide informed consent.
- Active bleeding or other reasons for which anticoagulation is contraindicated.
- Other indications requiring ongoing therapeutic dose of anticoagulation as deemed necessary by treating physicians (such as atrial fibrillation, mechanical heart valve, etc.).
- Anticoagulation has been permanently stopped or reduced to prophylactic dose for \> 5 days prior to enrollment for any reasons.
- Pregnancy or breast feeding in patients who are prescribed a direct oral anticoagulant.
- Concomitant use of strong inhibitors or inducers of both cytochrome P450 3A4 and P-glycoprotein in patients who are prescribed a direct oral anticoagulant.
- Cancer is in remission and CVC is removed prior to enrollment.
- Requirement of dual antiplatelet therapies.
- Platelet count \< 50 x 109/L or creatinine clearance \< 30 ml/min.
- Life expectancy of less than 3 months.
The study team makes the final eligibility decision.
Where it is enrolling
- Ottawa, Ontario, Canada
- Sault Ste. Marie, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Ottawa, Ontario, Canada; Sault Ste. Marie, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.